NCT04218123

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

As of yet, the cause of Meniere's disease is uncertain and there is no cure. Given the lack of high level evidence for treatments, we seek to perform a randomized, placebo-controlled, double-blind, crossover, pilot trial of venlafaxine for treating Meniere's disease. Venlafaxine is a safe and well-tolerated medication. It has never been trialed in Meniere's disease, but there is evidence that it could be effective in helping with vertigo attacks and other aspects of the disorder.

Conditions

• Meniere Disease

Interventions

Type	Name	Description
DRUG	Venlafaxine	Daily oral intake 37.5 mg
DRUG	Placebo oral tablet	Daily oral intake

Timeline

• Start date: 2020-02-05
• Primary completion: 2023-09-13
• Completion: 2023-09-14
• First posted: 2020-01-06
• Last updated: 2024-07-23
• Results posted: 2024-06-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study